~~<i id='23ACC5F8AB'><strike id='23ACC5F8AB'><tt id='23ACC5F8AB'><pre id='23ACC5F8AB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：focus 2025-10-02 23:25:57 - browse：3

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Akero's treatment for NASH falls short in cirrhosis study

focus

hotspot

leisure time

explore

knowledge

MollyFergusonforSTATAttheturnofthecentury,nearly18millionwomenintheUnitedStateswerebattlinghotflashe

WSS

Wellcome Trust names Røttingen as its new CEO

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

How doctors and nurses shape Google's AI

There’s a way to spot data fakery. All journals should be using it

explore

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Stanford president’s abrupt resignation sparks debate

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The stock market has soared this year, but will it last? Experts weigh in

Bright Health sells Medicare Advantage business to Molina

Eight reasons why you should get an updated Covid vaccine

Activists slam private health insurers over coverage restrictions

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Virginia high school admissions case could be legal follow

The stock market has soared this year, but will it last? Experts weigh in

hotspot

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Life sciences deals on track to hit lowest point since 2017

Telehealth startups are trying to fill the menopause care vacuum

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

There’s no way to know how good AI health technologies are

leisure time

explore

knowledge

knowledge